Evidence map›Paper›PMID 33691674›Full record

Observational studyBMC cancer2021

Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.

Annalisa Zeppellini, Stefania Galimberti, Biagio Eugenio Leone, Claudia Pacifico, Francesca Riva, Federica Cicchiello, Serena Capici, Claudia Maggioni, Luca Sala, Marina Elena Cazzaniga

Open access · goldAbstract readComparative StudyObservational Study
In one paragraph

Observational study in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. The immunology of human breast cancer.Nature reviews. Immunology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Annalisa ZeppelliniDepartment of Medical Oncology, ASST Monza, via Pergolesi, Monza, Italy.
Stefania GalimbertiSchool of Medicine and Surgery, Bicocca Bioinformatics Biostatistics and Bioimaging B4 Center, University of Milano - Bicocca, via Cadore, Monza, Italy. stefania.galimberti@unimib.it.ORCID http://orcid.org/0000-0003-1504-7242
Biagio Eugenio LeoneSchool of Medicine and Surgery, University of Milano - Bicocca, via Cadore, Monza, Italy.
Claudia PacificoSchool of Medicine and Surgery, Bicocca Bioinformatics Biostatistics and Bioimaging B4 Center, University of Milano - Bicocca, via Cadore, Monza, Italy.
Francesca RivaDepartment of Medical Oncology, ASST Monza, via Pergolesi, Monza, Italy.
Federica CicchielloDepartment of Medical Oncology, ASST Monza, via Pergolesi, Monza, Italy.
Serena CapiciPhase 1 Research Centre - ASST Monza, via Pergolesi, Monza, Italy.
Claudia MaggioniDepartment of Medical Oncology, ASST Monza, via Pergolesi, Monza, Italy.
Luca SalaDepartment of Medical Oncology, ASST Monza, via Pergolesi, Monza, Italy.
Marina Elena CazzanigaSchool of Medicine and Surgery, University of Milano - Bicocca, via Cadore, Monza, Italy.
University of Milano-Bicocca · ITAzienda Ospedaliera San Gerardo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor microenvironment (TME) is a dynamic setting and changes in TILs and their subpopulations are potential candidates to influence the metastatic process. Aim of this pilot study is to describe the changes occurring between primary breast cancers and their paired metastases in terms of TILs composition. To assess if these changes influence the process of metastasis development, we used a control group of patients.

methodsWe retrospectively identified 18 Luminal patients, for whom primary and metastatic tissue were available (cases) and 18 paired-matched patients (controls), not relapsed after at least 9 years of follow-up, and we quantified TILs and their composition (i.e. T CD8+ and CD4+/FOXP3+). The presence of TILs was defined as ≥10%.

resultsOur results showed that the microenvironment composition of relapsed patients was poor of TILs (median = 5%, I-III quartiles = 0.6-5%), CD8+ (2.5%, 0-5%) and CD4+/FOXP3 + (0%, 0-0.6%) in the primary tumor. Comparable results were observed in their related metastases (TILs 3.8%, 0.6-5%; CD8+ 0%, 0-1.3%; CD4+/FOXP3+ 0%,0-1.9%). On the contrary, the microenvironment in the control group was richer of TILs (5%, 5-17.5%) in comparison to cases, both in primary tumor (p = 0.035) and related metastases (p = 0.018). Although CD8+ in controls were similar to cases at primary tumor (p = 0.6498), but not at metastasis (p = 0.0223), they expressed only one part on the TILs subpopulations (p = 0.0060), while TILs in the cases at primary tumor were almost completely CD8+ (p = 0.5034).

conclusionsThese findings suggest that the lack of activation of immune system in the primary tumor might influence the multifactor process of cancer progression.

Indexed as

AgedAged, 80 and overBiopsyBreastBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantDisease ProgressionErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansLymphocytes, Tumor-InfiltratingMastectomyMiddle AgedNeoplasm Recurrence, LocalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenBreast CancerLuminalMicroenvironmentT CD4+ FOXP3+T CD8 +Tumor infiltrating lymphocytes (TILs)

Identifiers

PMID33691674
PMCPMC7944604
OpenAlexW3134041117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.